GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Operating Margin %

VRAX (Virax Biolabs Group) Operating Margin % : -57,580.00% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Virax Biolabs Group's Operating Income for the six months ended in Sep. 2024 was $-2.88 Mil. Virax Biolabs Group's Revenue for the six months ended in Sep. 2024 was $0.01 Mil. Therefore, Virax Biolabs Group's Operating Margin % for the quarter that ended in Sep. 2024 was -57,580.00%.

The historical rank and industry rank for Virax Biolabs Group's Operating Margin % or its related term are showing as below:

VRAX' s Operating Margin % Range Over the Past 10 Years
Min: -63700   Med: -2282.55   Max: -520.16
Current: -7387.06


VRAX's Operating Margin % is ranked worse than
90.32% of 992 companies
in the Biotechnology industry
Industry Median: -127.94 vs VRAX: -7387.06

Virax Biolabs Group's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Virax Biolabs Group's Operating Income for the six months ended in Sep. 2024 was $-2.88 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.28 Mil.

Warning Sign:

Virax Biolabs Group Ltd has never been profitable in the past 3 years. It lost money every year.


Virax Biolabs Group Operating Margin % Historical Data

The historical data trend for Virax Biolabs Group's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Operating Margin % Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Operating Margin %
-651.00 -520.16 - -63,700.00 -3,914.10

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -24,016.67 -143,066.67 -3,514.29 -4,250.00 -57,580.00

Competitive Comparison of Virax Biolabs Group's Operating Margin %

For the Biotechnology subindustry, Virax Biolabs Group's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Operating Margin % falls into.


;
;

Virax Biolabs Group Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Virax Biolabs Group's Operating Margin % for the fiscal year that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=-6.106 / 0.156
=-3,914.10 %

Virax Biolabs Group's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=-2.879 / 0.005
=-57,580.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virax Biolabs Group  (NAS:VRAX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Virax Biolabs Group Operating Margin % Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group Business Description

Traded in Other Exchanges
N/A
Address
Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.